Eptinezumab is a monoclonal immunoglobulin G1 (IgG1) antibody that binds to human calcitonin gene-related peptide (CGRP) with high specificity and high affinity for the CGRP α- and β-form. CGRP is a signaling molecule in the pathophysiology of migraine and cluster headache.

Eptinezumab is a monoclonal immunoglobulin G1 (IgG1) antibody that binds to human calcitonin gene-related peptide (CGRP) with high specificity and high affinity for the CGRP α- and β-form. CGRP is a signaling molecule in the pathophysiology of migraine and cluster headache.

Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors. The serotonin, dopamine, and noradrenaline neurotransmitter systems may be implicated in behavioral symptoms of dementia, including agitation.

*Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc.

Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors. The serotonergic, dopaminergic, and especially the noradrenergic systems are believed to be involved in PTSD symptomatology with re-experiencing, Negative cognition and mood, Avoidance and Arousal.

*Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc.

Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors. Serotonergic and Dopaminergic stabilization may directly address the pathways implicated in the BPD features of impulse aggression (SER), and emotional dysregulation, impulsivity, and cognitive disturbances (DA).

*Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc.

Aripiprazole is a small molecule. It acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and antagonist at serotonin 5-HT2A receptors. A 2-month formulation will serve as a treatment option when treating patients with Schizophrenia or Bipolar I disorder where long-acting treatment is needed.

*Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc.

Lu AG06466 is a small molecule and a highly selective inhibitor of monoacylglycerol lipase (MAGL), the primary enzyme responsible for the degradation of the endocannabinoid ligand 2-arachidonoylglycerol (2-AG). Enhancing the actions of 2-AG on CB1 and CB2 receptors may restore altered neuronal transmission and neuroinflammation and thereby it may produce beneficial effects across a range of symptoms and related indications including PTSD, Fibromyalgia and spasticity in patients with multiple sclerosis.

*MAGL: Monoacylglycerol lipase. PTSD, fibromyalgia, and MS spasticity studies have been initiated, one additional Phase Ib study within psychiatry/neurology will be explored during 2021.

Lu AG06479 is a small molecule and a highly selective inhibitor of monoacylglycerol lipase (MAGL), the primary enzyme responsible for the degradation of the endocannabinoid ligand 2-arachidonoylglycerol (2-AG). Enhancing 2-AG levels is a viable approach to restore brain homeostasis.

*MAGL: Monoacylglycerol lipase.

Lu AF82422 is a monoclonal antibody targeting alpha-synuclein. Misfolding, aggregation and extracellular spreading of alpha-synuclein is believed to play a major role in disease pathology and progression in Multiple System Atrophy (MSA), Parkinson’s disease and other neurodegenerative disorders.

Lu AF28996 is a small molecule with agonistic properties towards D1 and D2 receptors. Concerted D1 and D2 dopamine receptor stimulation may play an important role in motor control of Parkinson’s disease patients.

LU AG09222 is a monoclonal antibody designed to inhibit pituitary adenylate cyclase-activating polypeptide (PACAP) signaling for migraine prevention. PACAP has emerged as a signaling molecule in the pathophysiology of migraine.

*PACAP: Pituitary adenylate cyclase-activating polypeptide

Lu AF87908 (Tau mAb) is a monoclonal antibody targeting the pathological form of the protein tau which is believed to play a pivotal role in the development and progression of Alzheimer’s disease and other neurodegenerative disorders.